Coherus Oncology (CHRS) Cash from Investing Activities (QoQ) (2014 - 2026)
Coherus Oncology (CHRS) Cash from Investing Activities (QoQ) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.34% |
| Mar 31, 2026 | 1,180.16% |
| Dec 31, 2025 | 95.78% |
| Sep 30, 2025 | -114.53% |
| Jun 30, 2025 | 2,745.76% |
| Mar 31, 2025 | -3,126.20% |
| Dec 31, 2024 | -222.07% |
| Sep 30, 2024 | -98.39% |
| Jun 30, 2024 | -86.36% |
| Mar 31, 2024 | 475.98% |
| Dec 31, 2023 | -30.35% |
| Sep 30, 2023 | 22.20% |
| Jun 30, 2023 | 136.02% |
| Mar 31, 2023 | 113.49% |
| Dec 31, 2022 | -28,324.07% |
| Sep 30, 2022 | 48.07% |
| Jun 30, 2022 | 97.53% |
| Mar 31, 2022 | -133.13% |
| Dec 31, 2021 | 572.23% |
| Sep 30, 2021 | -32.20% |